EML4-ALK fusion gene is identified in approximately 3-13% of non-small cell lung cancer (NSCLC).     ///    "Early-phase clinical studies with Crizotinib, an ALK inhibitor, in NSCLC harboring EML4-ALK have demonstrated promising activity with high response rate and prolonged progression-free survival. "